問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Study Statistics

5576Cases

20022027

Total

5576

  • I

    615

  • I/II

    269

  • II

    1305

  • II/III

    138

  • III

    2775

  • IV

    109

  • Others

    363

Principal Investigator

2782Doctors

Co-Principal Investigator

8684Doctors

Hospital

123Sites

List

5576Cases

2021-03-01 - 2026-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-12-21 - 2023-12-31

Phase I

Completed
An open-label, first-in-human, single agent, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR442085 in patients with relapsed or refractory multiple myeloma

  • Condition/Disease

    relapsed or refractory multiple myeloma

  • Test Drug

    SAR442085

Participate Sites
2Sites

Recruiting2Sites

2022-01-01 - 2024-04-23

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-10-01 - 2024-12-31

Phase III

Completed
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis

  • Condition/Disease

    Relapsing Multiple Sclerosis

  • Test Drug

    SAR442168 60mg or Teriflunomide 14mg or placebo

Participate Sites
6Sites

Recruiting6Sites

2025-03-01 - 2027-12-31

Phase III

Active
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults

  • Condition/Disease

    Lichen Simplex Chronicus (LSC)

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB